3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
18
Metastatic Castration-resistant Prostate Cancer
3
Prostatic Neoplasms, Castration-Resistant
2
Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Prostate Cancer Metastatic
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm Metastasis
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistent Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Breast Neoplasms
1
Abiraterone Acetate
1
Interventions
enzalutamide
2
cabazitaxel
2
Prednisone
2
Androgen Antagonists
2
fludrocortisone acetate
1
darolutamide
1
XRP6258
1
Radiosurgery
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
Hydrocortisone
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostate Cancer Metastatic
×
Abiraterone Acetate
×
Clear all
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled